The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Research Report 2024
Synopsis
Gastroesophageal Junction Adenocarcinoma (GEJAC) is a type of cancer that occurs where the esophagus meets the stomach.
Global Gastroesophageal Junction Adenocarcinoma Therapeutics market is projected to reach US$ 17680 million in 2029, increasing from US$ 5478 million in 2022, with the CAGR of 18.0% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Gastroesophageal Junction Adenocarcinoma Therapeutics market research.
The gastroesophageal junction adenocarcinoma therapeutics market is driven by the increasing incidence of this aggressive cancer and the growing demand for effective treatment options. Gastroesophageal junction adenocarcinoma is a type of cancer that affects the junction between the esophagus and the stomach. The rise in risk factors, such as obesity, gastroesophageal reflux disease, and Helicobacter pylori infection, contributes to market growth. The development of targeted therapies, such as immune checkpoint inhibitors and HER2-targeted agents, has improved patient outcomes and expanded treatment options. However, the market also faces challenges, including the late diagnosis of the disease, as it is often detected at an advanced stage, and the limited effectiveness of current treatments in advanced cases. Additionally, the high cost of specialized therapies and the need for personalized treatment approaches can pose obstacles for both patients and healthcare systems. To succeed, companies must focus on research and development to provide innovative and targeted drug therapies, collaborate with healthcare providers to improve disease management, and address the challenges to meet the increasing demand for effective gastroesophageal junction adenocarcinoma therapeutics.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Gastroesophageal Junction Adenocarcinoma Therapeutics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Astellas Pharmaceuticals
AstraZeneca
Bayer
Beigene
Bristol-Myers Squibb
Daichii Sankyo
Elevar Therapeutics
Eli Lilly
FivePrime Therapeutics
Incyte
Macrogenics
Merck Co
Ono Pharmaceuticals
Roche
Taiho Pharmaceuticals
Zai Labs
ZymeWorks
Segment by Type
Drug
Surgery
Chemotherapy
Targeted Therapy
Segment by Application
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Gastroesophageal Junction Adenocarcinoma Therapeutics report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Gastroesophageal Junction Adenocarcinoma (GEJAC) is a type of cancer that occurs where the esophagus meets the stomach.
Global Gastroesophageal Junction Adenocarcinoma Therapeutics market is projected to reach US$ 17680 million in 2029, increasing from US$ 5478 million in 2022, with the CAGR of 18.0% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Gastroesophageal Junction Adenocarcinoma Therapeutics market research.
The gastroesophageal junction adenocarcinoma therapeutics market is driven by the increasing incidence of this aggressive cancer and the growing demand for effective treatment options. Gastroesophageal junction adenocarcinoma is a type of cancer that affects the junction between the esophagus and the stomach. The rise in risk factors, such as obesity, gastroesophageal reflux disease, and Helicobacter pylori infection, contributes to market growth. The development of targeted therapies, such as immune checkpoint inhibitors and HER2-targeted agents, has improved patient outcomes and expanded treatment options. However, the market also faces challenges, including the late diagnosis of the disease, as it is often detected at an advanced stage, and the limited effectiveness of current treatments in advanced cases. Additionally, the high cost of specialized therapies and the need for personalized treatment approaches can pose obstacles for both patients and healthcare systems. To succeed, companies must focus on research and development to provide innovative and targeted drug therapies, collaborate with healthcare providers to improve disease management, and address the challenges to meet the increasing demand for effective gastroesophageal junction adenocarcinoma therapeutics.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Gastroesophageal Junction Adenocarcinoma Therapeutics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Astellas Pharmaceuticals
AstraZeneca
Bayer
Beigene
Bristol-Myers Squibb
Daichii Sankyo
Elevar Therapeutics
Eli Lilly
FivePrime Therapeutics
Incyte
Macrogenics
Merck Co
Ono Pharmaceuticals
Roche
Taiho Pharmaceuticals
Zai Labs
ZymeWorks
Segment by Type
Drug
Surgery
Chemotherapy
Targeted Therapy
Segment by Application
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Gastroesophageal Junction Adenocarcinoma Therapeutics report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Drug
1.2.3 Surgery
1.2.4 Chemotherapy
1.2.5 Targeted Therapy
1.3 Market by Application
1.3.1 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Online Pharmacy
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Perspective (2018-2029)
2.2 Gastroesophageal Junction Adenocarcinoma Therapeutics Growth Trends by Region
2.2.1 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Gastroesophageal Junction Adenocarcinoma Therapeutics Historic Market Size by Region (2018-2023)
2.2.3 Gastroesophageal Junction Adenocarcinoma Therapeutics Forecasted Market Size by Region (2024-2029)
2.3 Gastroesophageal Junction Adenocarcinoma Therapeutics Market Dynamics
2.3.1 Gastroesophageal Junction Adenocarcinoma Therapeutics Industry Trends
2.3.2 Gastroesophageal Junction Adenocarcinoma Therapeutics Market Drivers
2.3.3 Gastroesophageal Junction Adenocarcinoma Therapeutics Market Challenges
2.3.4 Gastroesophageal Junction Adenocarcinoma Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Gastroesophageal Junction Adenocarcinoma Therapeutics Players by Revenue
3.1.1 Global Top Gastroesophageal Junction Adenocarcinoma Therapeutics Players by Revenue (2018-2023)
3.1.2 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue Market Share by Players (2018-2023)
3.2 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue
3.4 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Concentration Ratio
3.4.1 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue in 2022
3.5 Gastroesophageal Junction Adenocarcinoma Therapeutics Key Players Head office and Area Served
3.6 Key Players Gastroesophageal Junction Adenocarcinoma Therapeutics Product Solution and Service
3.7 Date of Enter into Gastroesophageal Junction Adenocarcinoma Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Gastroesophageal Junction Adenocarcinoma Therapeutics Breakdown Data by Type
4.1 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Historic Market Size by Type (2018-2023)
4.2 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Forecasted Market Size by Type (2024-2029)
5 Gastroesophageal Junction Adenocarcinoma Therapeutics Breakdown Data by Application
5.1 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Historic Market Size by Application (2018-2023)
5.2 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size (2018-2029)
6.2 North America Gastroesophageal Junction Adenocarcinoma Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Country (2018-2023)
6.4 North America Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size (2018-2029)
7.2 Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Country (2018-2023)
7.4 Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size (2018-2029)
8.2 Asia-Pacific Gastroesophageal Junction Adenocarcinoma Therapeutics Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Region (2018-2023)
8.4 Asia-Pacific Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size (2018-2029)
9.2 Latin America Gastroesophageal Junction Adenocarcinoma Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Country (2018-2023)
9.4 Latin America Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size (2018-2029)
10.2 Middle East & Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Country (2018-2023)
10.4 Middle East & Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Astellas Pharmaceuticals
11.1.1 Astellas Pharmaceuticals Company Detail
11.1.2 Astellas Pharmaceuticals Business Overview
11.1.3 Astellas Pharmaceuticals Gastroesophageal Junction Adenocarcinoma Therapeutics Introduction
11.1.4 Astellas Pharmaceuticals Revenue in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2018-2023)
11.1.5 Astellas Pharmaceuticals Recent Development
11.2 AstraZeneca
11.2.1 AstraZeneca Company Detail
11.2.2 AstraZeneca Business Overview
11.2.3 AstraZeneca Gastroesophageal Junction Adenocarcinoma Therapeutics Introduction
11.2.4 AstraZeneca Revenue in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2018-2023)
11.2.5 AstraZeneca Recent Development
11.3 Bayer
11.3.1 Bayer Company Detail
11.3.2 Bayer Business Overview
11.3.3 Bayer Gastroesophageal Junction Adenocarcinoma Therapeutics Introduction
11.3.4 Bayer Revenue in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2018-2023)
11.3.5 Bayer Recent Development
11.4 Beigene
11.4.1 Beigene Company Detail
11.4.2 Beigene Business Overview
11.4.3 Beigene Gastroesophageal Junction Adenocarcinoma Therapeutics Introduction
11.4.4 Beigene Revenue in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2018-2023)
11.4.5 Beigene Recent Development
11.5 Bristol-Myers Squibb
11.5.1 Bristol-Myers Squibb Company Detail
11.5.2 Bristol-Myers Squibb Business Overview
11.5.3 Bristol-Myers Squibb Gastroesophageal Junction Adenocarcinoma Therapeutics Introduction
11.5.4 Bristol-Myers Squibb Revenue in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2018-2023)
11.5.5 Bristol-Myers Squibb Recent Development
11.6 Daichii Sankyo
11.6.1 Daichii Sankyo Company Detail
11.6.2 Daichii Sankyo Business Overview
11.6.3 Daichii Sankyo Gastroesophageal Junction Adenocarcinoma Therapeutics Introduction
11.6.4 Daichii Sankyo Revenue in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2018-2023)
11.6.5 Daichii Sankyo Recent Development
11.7 Elevar Therapeutics
11.7.1 Elevar Therapeutics Company Detail
11.7.2 Elevar Therapeutics Business Overview
11.7.3 Elevar Therapeutics Gastroesophageal Junction Adenocarcinoma Therapeutics Introduction
11.7.4 Elevar Therapeutics Revenue in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2018-2023)
11.7.5 Elevar Therapeutics Recent Development
11.8 Eli Lilly
11.8.1 Eli Lilly Company Detail
11.8.2 Eli Lilly Business Overview
11.8.3 Eli Lilly Gastroesophageal Junction Adenocarcinoma Therapeutics Introduction
11.8.4 Eli Lilly Revenue in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2018-2023)
11.8.5 Eli Lilly Recent Development
11.9 FivePrime Therapeutics
11.9.1 FivePrime Therapeutics Company Detail
11.9.2 FivePrime Therapeutics Business Overview
11.9.3 FivePrime Therapeutics Gastroesophageal Junction Adenocarcinoma Therapeutics Introduction
11.9.4 FivePrime Therapeutics Revenue in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2018-2023)
11.9.5 FivePrime Therapeutics Recent Development
11.10 Incyte
11.10.1 Incyte Company Detail
11.10.2 Incyte Business Overview
11.10.3 Incyte Gastroesophageal Junction Adenocarcinoma Therapeutics Introduction
11.10.4 Incyte Revenue in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2018-2023)
11.10.5 Incyte Recent Development
11.11 Macrogenics
11.11.1 Macrogenics Company Detail
11.11.2 Macrogenics Business Overview
11.11.3 Macrogenics Gastroesophageal Junction Adenocarcinoma Therapeutics Introduction
11.11.4 Macrogenics Revenue in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2018-2023)
11.11.5 Macrogenics Recent Development
11.12 Merck Co
11.12.1 Merck Co Company Detail
11.12.2 Merck Co Business Overview
11.12.3 Merck Co Gastroesophageal Junction Adenocarcinoma Therapeutics Introduction
11.12.4 Merck Co Revenue in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2018-2023)
11.12.5 Merck Co Recent Development
11.13 Ono Pharmaceuticals
11.13.1 Ono Pharmaceuticals Company Detail
11.13.2 Ono Pharmaceuticals Business Overview
11.13.3 Ono Pharmaceuticals Gastroesophageal Junction Adenocarcinoma Therapeutics Introduction
11.13.4 Ono Pharmaceuticals Revenue in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2018-2023)
11.13.5 Ono Pharmaceuticals Recent Development
11.14 Roche
11.14.1 Roche Company Detail
11.14.2 Roche Business Overview
11.14.3 Roche Gastroesophageal Junction Adenocarcinoma Therapeutics Introduction
11.14.4 Roche Revenue in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2018-2023)
11.14.5 Roche Recent Development
11.15 Taiho Pharmaceuticals
11.15.1 Taiho Pharmaceuticals Company Detail
11.15.2 Taiho Pharmaceuticals Business Overview
11.15.3 Taiho Pharmaceuticals Gastroesophageal Junction Adenocarcinoma Therapeutics Introduction
11.15.4 Taiho Pharmaceuticals Revenue in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2018-2023)
11.15.5 Taiho Pharmaceuticals Recent Development
11.16 Zai Labs
11.16.1 Zai Labs Company Detail
11.16.2 Zai Labs Business Overview
11.16.3 Zai Labs Gastroesophageal Junction Adenocarcinoma Therapeutics Introduction
11.16.4 Zai Labs Revenue in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2018-2023)
11.16.5 Zai Labs Recent Development
11.17 ZymeWorks
11.17.1 ZymeWorks Company Detail
11.17.2 ZymeWorks Business Overview
11.17.3 ZymeWorks Gastroesophageal Junction Adenocarcinoma Therapeutics Introduction
11.17.4 ZymeWorks Revenue in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2018-2023)
11.17.5 ZymeWorks Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
